179 results about "Somatotropic hormone" patented technology

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention relates to the technical field of microorganisms and bio-organic fertilizers, and particularly discloses a bio-organic fertilizer for preventing and treating rhizome diseases of horseradish and application of the bio-organic fertilizer, the bio-organic fertilizer comprises the following components: component A: a bacillus velezensis microbial inoculum with the preservation number of CCTCC NO: M 2022923 and a trichoderma yunnanense microbial inoculum with the preservation number of CCTCC NO: M 2025645; the component B is prepared from soybean meal, vinegar residues, charcoal, wollastonite powder and allicin. The biological organic fertilizer disclosed by the invention can be used for increasing the content of growth hormones such as salicylic acid (SA), jasmonic acid (JA) and ethylene (ET) and phytoalexin as well as the activity of chitinase and beta-1, 3-glucanase of a wasabi root system, and has a relatively good prevention and treatment effect on a black heart disease caused by infection of phoma wabi Yokog and a soft rot disease caused by infection of pectobacterium carotovorum subsp. Carotovorum (Pcc). The biological organic fertilizer disclosed by the invention has a relatively good prevention and treatment effect on the soft rot disease caused by infection of the phoma wabi Yokog and a relatively good prevention and treatment effect on the soft rot disease caused by infection of the phoma wabi subsp. Carotovorum (Pcc).

The invention discloses application of a growth hormone receptor antagonist and a nucleic acid molecule in preparation of a medicine for preventing or treating retinal neovascularization diseases, and relates to the technical field of retinal neovascularization. The invention finds that the growth hormone receptor antagonist or the blocking reagent can effectively intervene the occurrence and development of the neovascular retina disease and improve the symptom of the disease. In addition, the transcription level of the encoding gene of the growth hormone receptor is reduced in a gene editing mode, and the pathological vascular change of the retinal neovascular disease can be effectively improved by knocking out the retina GHR, so that the pathological neovascular growth of the retina is reduced, and vascular exudation and inflammatory response are reduced. The invention provides a new direction for the treatment of retinal neovascular diseases, and provides a new choice for patients intolerant or unresponsive to anti-VEGF (Vascular Endothelial Growth Factor) treatment.

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.

The invention provides a preparation method of yak bone collagen peptide, a composition for promoting skeletal development and application of the composition, and relates to the technical field of health food. The preparation method comprises the following steps: carrying out ultrasonic pretreatment on yak bones, and degreasing through supercritical CO2 to obtain a degreased product; mixing the degreased product with a fishy smell removing agent to obtain a fishy smell removing product; the fishy smell removing agent is an aqueous solution of a plant extract; the plant extract is selected from at least one of amomum tsao-ko extract, turmeric extract, green tea extract or momordica grosvenori extract; the fishy smell removal product is subjected to an enzymatic hydrolysis reaction through an immobilized compound enzyme reactor, wherein the compound enzyme is prolyl endopeptidase, papain and ficin; obtaining a crude product; carrying out ultrafiltration by adopting a filter membrane with the molecular weight cut-off of 1kDa, and adsorbing through macroporous resin. The yak bone collagen peptide and the composition prepared by the invention can obviously improve the body length, promote the skeletal development and promote the secretion of growth hormone, and meet the growth requirements of children.

The invention discloses a marine sediment bacillus CK22 and application thereof, and belongs to the field of microorganisms, the strain is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M20251027. The strain disclosed by the invention has the capabilities of dissolving potassium, dissolving calcium and magnesium and secreting plant growth hormone and cytokinin, particularly has very excellent capability of dissolving magnesium element, is improved by more than 20 times compared with a control group, has excellent comprehensive capability, and can be used for preparing a microbial fertilizer for promoting the growth of crops.

The invention relates to the technical field of medicine, in particular to an early evaluation method for endocrine remission of pituitary growth hormone adenoma based on low Knosp grading, which comprises the following steps: acquiring preoperative and postoperative image data and preoperative and postoperative clinical data of a patient with low Knosp grading pituitary growth hormone adenoma; extracting imaging features used for early evaluation of postoperative endocrine remission from the preoperative and postoperative image data; extracting clinical features for early evaluation of postoperative endocrine remission from the preoperative and postoperative clinical data; and performing statistical analysis on the iconography characteristics and the clinical characteristics to obtain an early evaluation result of postoperative endocrine remission. According to the method, risk factors related to whether low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission can be relieved or not are screened out, then a prediction model is established through a statistical method, and then early prediction of low-Knosp graded pituitary growth hormone adenoma postoperative endocrine remission is achieved.

The invention discloses a siraitia grosvenorii tissue culture seedling ex-vitro rooting method, belongs to the technical field of plant tissue culture, and mainly solves the problems of long rooting time, untidy root development and low transplanting survival rate in the traditional tissue culture seedling ex-vitro rooting technology. The method comprises the following steps: selecting young branches to prepare sterile explants, and performing hormone-induced culture to obtain robust tissue culture seedlings; a growth hormone combination with a specific ratio is adopted in the rooting pre-culture stage; humidity change is controlled through three-stage gradient seedling hardening; the tissue culture seedlings are transplanted to a matrix after being soaked in a 200-350 mg / L ABT rooting solution. The method remarkably shortens the rooting time, improves the root strength, improves the transplanting survival rate, and can be efficiently used for large-scale production of the virus-free seedlings of momordica grosvenori and resist environmental stress such as late spring coldness.

The application discloses application of SbWOX gene and SbBBM gene in corn breeding and a corn genetic transformation method, and relates to a bioengineering technology.The application provides a nucleic acid molecule with co-expression of SbWOX protein gene and SbBBM protein gene, and corresponding gene co-expression vectors and microbial transformants.The application also provides application of the co-expression of the SbWOX gene and the SbBBM gene in the corn genetic transformation method.The application obtains corresponding genes and mutant proteins based on the SbWOX gene and the SbBBM gene of sorghum, the two genes are co-expressed in the corn genetic transformation process, even without adding plant growth hormones in the antibiotic screening medium in the tissue culture process, the plant genetic transformation process can be normally completed, and the transformation efficiency and the regeneration efficiency of the corn can be remarkably improved, the transformation rate reaches 10.42%, and the differentiation rate reaches 32.89%.

The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.

The present invention describes for the first time a method for preventing and / or reversing the phenomenon of premature senescence of skin cells and complex chronic wounds, characterized in that an effective amount of the growth hormone secretagogue peptide GHRP6 is applied. Also object of the present invention is a method for treating cases of complex chronic wounds that have developed primary or secondary refractoriness caused by the development of a cellular senescence process, transforming them from refractory wounds to responsive wounds in the presence of proliferative agents with which they unexpectedly manage to reverse and restart the healing process. Complex chronic wounds include cases of diabetic foot ulcers, venous ulcers, pressure ulcers, radiation ulcers, and other types of chronic wounds that are characterized by refractoriness to all types of treatment. These cases currently have no effective treatments.

The invention discloses a taxodium Zhongshanha lateral branch development related gene ThERF053 as well as an expression protein and application thereof, and belongs to the technical field of plant genetic engineering. The taxodium Zhongshanha ThERF053 gene is obtained through cloning, the nucleotide sequence of the taxodium Zhongshanha ThERF053 gene is shown as SEQ ID NO: 1, and the amino acid sequence of expression protein is shown as SEQ ID NO: 2. The ThERF053 gene is transferred into a model plant poplar, the expression quantity of the ThERF053 transgenic poplar is increased by 980-5100 times, and meanwhile, the content of growth hormone IAA in the transgenic poplar plant is lower than that of a control plant. After growing for 30 days, the phenomenon that lateral branches are obviously increased occurs in the transgenic populus sutchuenensis. The experimental results show that the ThERF053 is a key gene for positively regulating lateral branch development of Taxodium Zhongshanha and has important application value in molecular breeding of Taxodium Zhongshanha and related tree species.

The invention relates to the technical field of biological medicine, in particular to polypeptide for promoting release of growth hormone and application of the polypeptide, the polypeptide is shown as a formula (I), and in addition, the invention further provides application of the polypeptide shown as the formula (I) in preparation of medicine for diagnosing and / or treating diseases related to human growth hormone deficiency. Formula (I)

The present technology generally relates to peptides that bind to the growth hormone receptor (GhR), to peptides that bind to the GhR and have antagonistic activity, and to compositions comprising such peptides.

The present invention provides processes for producing a bioengineered lung (BEL) from an acellular lung matrix that has been treated with growth hormones, seeded with primary lung cells, and cultured in a bioreactor. Also provided are BELs and methods of transplanting the BEL into a subject in need of a lung transplant, and methods for using BELs for the study of the lung microbiome and its role in lung development and remodeling.

Disclosed are a compound shown in formula I and racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, a preparation method thereof, and a use thereof as a GHSR agonist in the preparation of a drug for the diagnosis, prevention and / or treatment of growth hormone-dependent diseases, the structure of formula I is as follows:

A method for producing a metabolism-activated liver organ, comprising a step for culturing primary hepatocytes or hepatocyte-like cells in a differential medium to obtain a metabolism-activated liver organ, the differential medium is a medium containing a glucocorticoid receptor agonist and one or two selected from the group consisting of a growth hormone receptor agonist and a prolactin receptor agonist.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

The present disclosure relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in treating growth hormone deficiency or a condition associated with an abnormal reduction in growth hormone (GH) secretion in a subject that has adequate GH secretion potential.

The invention belongs to the technical field of experimental animal nutriology and sterile animal culture, and particularly relates to a vitamin compound for prolonging the survival time of sterile zebra fish and a preparation method of the vitamin compound. The vitamin compound is prepared from the following components in parts by mass: 600 to 1000 parts of vitamin A, 4000 to 6000 parts of vitamin C, 10 to 30 parts of vitamin D3, 1500 to 2200 parts of vitamin E, 80 to 120 parts of vitamin K3, 15000 to 25000 parts of compound B vitamins and sterile culture water. The preparation method comprises the following steps: dissolving the vitamin raw materials in sterile culture water, performing ultrasonic assisted dissolution, and then filtering and sterilizing to obtain the vitamin supplement. When the vitamin supplement is used for feeding the sterile zebra fish, the survival time of the sterile zebra fish can be obviously prolonged, and the expression level of growth hormone genes and insulin-like growth factor genes can be up-regulated. The application value of the sterile zebrafish in scientific research is further expanded.

The invention relates to the technical field of poultry breeding, and particularly discloses an antibiotic-free breeding method for improving the quality of old yard black chickens based on compound plant alternate feeding, and in the growth process of chickens, plant complementary food and basic ration without antibiotics and growth promoting hormone are added for mixed feeding; the adding method of the plant complementary food comprises the following steps: (1) forming a three-day alternating unit according to the sequence of feeding fresh Chinese chives on the first day, feeding fresh wild wormwood on the second day and feeding fresh wild banana trees on the third day, and circularly repeating the mode until the chickens are slaughtered; (2) the adding proportion of the plant complementary food is increased along with the day age of the chickens, and the adding proportion is the mass percentage of the total feeding weight of the day. According to the antibiotic-free breeding method, the specific composite plant feed is adopted for alternate feeding, and the meat flavor, the nutritional value and the health level of the chickens are remarkably improved through functional complementation and time sequence collaboration of plant active ingredients.

The invention belongs to the technical field of biological medicines, and discloses a novel long-acting recombinant human growth hormone fusion protein. The fusion protein is obtained by fusion expression of human growth hormone (hGH) and an anti-human albumin nano antibody (VHH). And the long-acting principle is that the clearance rate is reduced by reversibly and widely combining with albumin with endogenous circulation. The fusion protein has the characteristics that 1, the fusion protein is obtained by fusion expression of two functional domains of hGH and VHH, hGH sequence mutation and complex chemical modification are not involved, the preparation method is simpler, and the sample uniformity is better; 2, in the fusion protein, the N end of the hGH protein has no additional structure, and the VHH functional domain is connected to the C end of the hGH, so that the influence on the activity of the hGH is reduced; and 3, animal efficacy results show that the fusion protein has a long-acting effect.

The application discloses a transdermal patch special for children with dwarfism, and relates to the technical field of medical treatment, which comprises a patch main body and a needle cylinder, and a fixed plate is fixedly connected to the inside of the patch main body, and the top and the bottom of the fixed plate are penetrated by the needle cylinder; the top of the needle cylinder is provided with a pressing plate, the bottom of the pressing plate is provided with a stand column on the two sides of the needle cylinder, the bottom of the two stand columns is arranged in the inside of the fixed plate and is slidably connected with the fixed plate; the two stand columns are both sleeved with a spring one; the top of the pressing plate is provided with a clamping groove, the bottom of the clamping groove is communicated with the needle cylinder, and a clamping seat is arranged in the clamping groove; the top of the pressing plate is provided with a fence; the two sides of the pressing plate are both provided with a connecting rod, one end of the connecting rod is connected with the pressing plate, and the other end penetrates through the top of the patch main body; the two sides of the patch main body close to the bottom are both provided with a sticking layer; and the two sides of the inside of the patch main body are both provided with a negative pressure sponge layer. The burden of the children with dwarfism is relieved, growth hormone injection treatment is facilitated, and the skin redness and swelling caused after growth hormone injection can be effectively prevented and treated.

The present invention relates to a customizable injectable solution comprising Human Growth Hormone (HGH), Insulin-like Growth Factor 1 (IGF-1), or a growth hormone secretagogue such as sermorelin or ipamorelin, combined with a blend of nutrients including amino acids, vitamins, electrolytes, functional mushroom extracts, and optionally mushroom mycelium. The solution is delivered via a dual-chamber syringe to preserve component stability, with mixing occurring immediately before administration. The formulation is suitable for subcutaneous, intramuscular, or intravenous injection and may be tailored for muscle growth, cognitive performance, immune support, or neuroregeneration. The invention also contemplates injectable formulations of functional mushrooms alone, as well as alternative delivery methods such as sublingual troches containing GH-inducing peptides, functional mushrooms, and ketamine. This system provides a versatile, bioavailable, and clinically adaptable approach to personalized health optimization.

The invention discloses a composition for promoting growth hormone secretion and nutrient absorption. The composition comprises gamma-aminobutyric acid, composite minerals, composite vitamins, lactobacillus fermentum and seasoning auxiliary materials. The preparation method comprises the following steps: (1) putting the weighed materials into a wet granulator, adding water according to the proportion, and granulating; (2) drying the granulated material, and controlling the moisture to be within 5%; and (3) adding seasoning auxiliary materials into the dried material particles, and mixing to obtain the composition. The composition provided by the invention provides enough nutrients while the gamma-aminobutyric acid promotes the secretion of growth hormones, so that the effects can be better exerted, and the aim of achieving a higher expected effect is achieved.

The invention relates to the technical field of medicines, in particular to application of a growth hormone releasing peptide Ghrelin receptor in itching intervention. By adjusting the activity of the receptor, the invention provides a new strategy for intervening pruritus: activation of the Ghrelin receptor can be used for inducing pruritus so as to construct a disease model; and inhibiting the Ghrelin receptor is used for preventing or treating pruritus, and the pruritus comprises acute pruritus and chronic pruritus. In specific implementation, the inhibition of the receptor is realized by applying the Ghrelin receptor antagonist, and the activation of the receptor is realized by applying the Ghrelin receptor agonist. Therefore, by targeting the Ghrelin receptor, controllable induction and efficient inhibition of pruritus are realized, mechanism innovation, treatment practicability and conversion feasibility are integrated, and a breakthrough strategy is provided for prevention and treatment of pruritus-related diseases.

To provide a pharmaceutical composition for treating lung inflammation in a mammalian subject having a granulomatous pulmonary disease.SOLUTION: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a GHRH antagonist.SELECTED DRAWING: None

The present disclosure relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in treating growth hormone deficiency or a condition associated with an abnormal reduction in growth hormone (GH) secretion in a subject that has adequate GH secretion potential.

The invention belongs to the technical field of biological medicines, and relates to a method for promoting synthesis and secretion of growth hormones by bovine gland pituitary cells, in particular to a method for promoting synthesis and secretion of growth hormones by melatonin. In-vitro experiments show that the melatonin can improve the level of adenosine cyclophosphate in cells, promote phosphorylation of PKA protein, promote expression of FOXO1 protein, combine the FOXO1 protein with a promoter of a Gh1 gene and promote synthesis and secretion of growth hormone by combining melatonin receptors in bovine pituitary cells. The application value of the melatonin in the fields of animal growth promotion, growth hormone deficiency treatment and the like is shown.